Figure 2.
Distribution of wild-type and different MRMs in M. genitalium-positive cases: (a) before the implementation of the M. genitalium diagnostics with macrolide-resistance detection, n = 21 (pre-RGT group) [19]; (b) after the implementation of the M. genitalium diagnostics with macrolide-resistance detection, n = 18 (RGT current study group).